[1]
|
Van de Wiele, T., Van Praet, J.T., Marzorati, M., Drennan, M.B. and Elewaut, D. (2016) How the Microbiota Shapes Rheumatic Diseases. Nature Reviews Rheumatology, 12, 398-411. https://doi.org/10.1038/nrrheum.2016.85
|
[2]
|
Lynch, S.V. and Pedersen, O. (2016) The Human Intestinal Micro-biome in Health and Disease. The New England Journal of Medicine, 375, 2369-2379. https://doi.org/10.1056/NEJMra1600266
|
[3]
|
Zhuang, H., Cheng, L., Wang, Y., et al. (2019) Dysbiosis of the Gut Microbiome in Lung Cancer. Frontiers in Cellular and Infection Microbiology, 9, Article 112. https://doi.org/10.3389/fcimb.2019.00112
|
[4]
|
Zheng, Y., Fang, Z., Xue, Y., et al. (2020) Specific Gut Microbi-ome Signature Predicts the Early-Stage Lung Cancer. Gut Microbes, 11, 1030-1042. https://doi.org/10.1080/19490976.2020.1737487
|
[5]
|
Vernocchi, P., Gili, T., Conte, F., et al. (2020) Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 21, Article 8730. https://doi.org/10.3390/ijms21228730
|
[6]
|
袁文杰, 郭亚琼, 韩毅, 等. 非小细胞肺癌患者肠道微生物特征分析[J]. 微生物学报, 2021, 61(9): 2776-2790.
|
[7]
|
安瑞. 肺癌患者肠道微生物群落结构特征的初步研究[D]: [硕士或博士学位论文]. 杭州: 南京医科大学, 2021.
|
[8]
|
Liu, F., Li, J., Guan, Y., et al. (2019) Dysbiosis of the Gut Mi-crobiome Is Associated with Tumor Biomarkers in Lung Cancer. International Journal of Biological Sciences, 15, 2381-2392. https://doi.org/10.7150/ijbs.35980
|
[9]
|
Weinberg, F., Dickson, R.P., Nagrath, D. and Ramnath, N. (2020) The Lung Microbiome: A Central Mediator of Host Inflammation and Metabolism in Lung Cancer Patients? Cancers, 13, Article 13.
https://doi.org/10.3390/cancers13010013
|
[10]
|
Lu, H., Gao, N.L., Tong, F., et al. (2021) Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant Metastasis. Microbiology Spectrum, 9, e00802-21.
https://doi.org/10.1128/Spectrum.00802-21
|
[11]
|
Ma, Y., Qiu, M.T., Wang, S.S., et al. (2021) Distinct Tumor Bac-terial Microbiome in Lung Adenocarcinomas Manifested as Radiological Subsolid Nodules. Translational Oncology, 14, Article ID: 101050.
https://doi.org/10.1016/j.tranon.2021.101050
|
[12]
|
Lim, M.Y., Hong, S., Hwang, K.H., et al. (2021) Diagnostic and Prognostic Potential of the Oral and Gut Microbiome for Lung Adenocarcinoma. Clinical and Translational Medicine, 11, e508. https://doi.org/10.1002/ctm2.508
|
[13]
|
He, Y., Wen, Q., Yao, F., et al. (2017) Gut-Lung Axis: The Microbial Contributions and Clinical Implications. Critical Reviews in Microbiology, 43, 81-95. https://doi.org/10.1080/1040841X.2016.1176988
|
[14]
|
Schuijt, T.J., Lankelma, J.M., Scicluna, B.P., et al. (2016) The Gut Microbiota Plays a Protective Role in the Host Defence against Pneumococcal Pneumonia. Gut, 65, 575-583. https://doi.org/10.1136/gutjnl-2015-309728
|
[15]
|
Atarashi, K., Tanoue, T., Ando, M., et al. (2015) Th17 Cell In-duction by Adhesion of Microbes to Intestinal Epithelial Cells. Cell, 163, 367-380. https://doi.org/10.1016/j.cell.2015.08.058
|
[16]
|
Bradley, C.P., Teng, F., Felix, K.M., et al. (2017) Segmented Fila-mentous Bacteria Provoke Lung Autoimmunity by Inducing Gut-Lung Axis Th17 Cells Expressing Dual TCRs. Cell Host Microbe, 2, 697-704.E4.
https://doi.org/10.1016/j.chom.2017.10.007
|
[17]
|
Birchenough, G.M., Nystrom, E.E., Johansson, M.E., et al. (2016) A Sentinel Goblet Cell Guards the Colonic Crypt by Triggering Nlrp6-Dependent Muc2 Secretion. Science, 352, 1535-1542. https://doi.org/10.1126/science.aaf7419
|
[18]
|
Gui, Q., Li, H., Wang, A., et al. (2020) The Association between Gut Butyrate-Producing Bacteria and Non-Small-Cell Lung Cancer. Journal of Clinical Laboratory Analysis, 34, e23318. https://doi.org/10.1002/jcla.23318
|
[19]
|
Dang, A.T. and Marsland, B.J. (2019) Microbes, Metabolites, and the Gut-Lung Axis. Mucosal Immunology, 12, 843-850. https://doi.org/10.1038/s41385-019-0160-6
|
[20]
|
Tan, J., McKenzie, C., Potamitis, M., et al. (2014) The Role of Short-Chain Fatty Acids in Health and Disease. Advances in Im-munology, 121, 91-119. https://doi.org/10.1016/B978-0-12-800100-4.00003-9
|
[21]
|
Chang, P.V., Hao, L., Offer-manns, S. and Medzhitov, R. (2014) The Microbial Metabolite Butyrate Regulates Intestinal Macrophage Function via Histone Deacetylase Inhibition. Proceedings of the National Academy of Sciences of the United States of America, 111, 2247-2252. https://doi.org/10.1073/pnas.1322269111
|
[22]
|
Vieira, R.S., Castoldi, A., Basso, P.J., et al. (2019) Bu-tyrate Attenuates Lung Inflammation by Negatively Modulating Th9 Cells. Frontiers in Immunology, 10, Article 67. https://doi.org/10.3389/fimmu.2019.00067
|
[23]
|
Bachem, A., Makhlouf, C., Binger, K.J., et al. (2019) Microbio-ta-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8+ T Cells. Immunity, 51, 285-297.E5.
https://doi.org/10.1016/j.immuni.2019.06.002
|
[24]
|
Kim, K., Kwon, O., Ryu, T.Y., et al. (2019) Propionate of a Microbiota Metabolite Induces Cell Apoptosis and Cell Cycle Arrest in Lung Cancer. Molecular Medicine Reports, 20, 1569-1574. https://doi.org/10.3892/mmr.2019.10431
|
[25]
|
Gaucher, L., Adda, L., Séjourné, A., et al. (2021) Asso-ciations between Dysbiosis-Inducing Drugs, Overall Survival and Tumor Response in Patients Treated with Immune Checkpoint Inhibitors. Therapeutic Advances in Medical Oncology, 13. https://doi.org/10.1177/17588359211000591
|
[26]
|
Tinsley, N., Zhou, C., Tan, G., et al. (2020) Cumulative Antibi-otic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. Oncologist, 25, 55-63. https://doi.org/10.1634/theoncologist.2019-0160
|
[27]
|
Derosa, L., Hellmann, M.D., Spaziano, M., et al. (2018) Negative Association of Antibiotics on Clinical Activity of Immune Checkpoint Inhibitors in Patients with Ad-vanced Renal Cell and Non-Small-Cell Lung Cancer. Annals of Oncology, 29, 1437-1444. https://doi.org/10.1093/annonc/mdy103
|
[28]
|
Ochi, N., Ichihara, E., Takigawa, N., et al. (2021) The Effects of An-tibiotics on the Efficacy of Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer Differ Based on PD-L1 Expression. European Journal of Cancer, 149, 73-81. https://doi.org/10.1016/j.ejca.2021.02.040
|
[29]
|
Hakozaki, T., Richard, C., Elkrief, A., et al. (2020) The Gut Micro-biome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Immunology Research, 8, 1243-1250.
https://doi.org/10.1158/2326-6066.CIR-20-0196
|
[30]
|
Ouaknine Krief, J., de Tauriers P.H., Dumenil, C., et al. (2019) Role of Antibiotic Use, Plasma Citrulline and Blood Microbiome in Advanced Non-Small Cell Lung Cancer Pa-tients Treated with Nivolumab. Journal for ImmunoTherapy of Cancer, 7, Article 176. https://doi.org/10.1186/s40425-019-0658-1
|
[31]
|
Nyein, A.F., Bari, S., Hogue, S., et al. (2022) Effect of Prior An-tibiotic or Chemotherapy Treatment on Immunotherapy Response in Non-Small Cell Lung Cancer. BMC Cancer, 22, Ar-ticle No. 101.
https://doi.org/10.1186/s12885-022-09210-2
|
[32]
|
Itzstein, M.S.V., Gonugunta, A.S., Sheffield, T., et al. (2022) Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint In-hibitor Therapy. Cancers, 14, Article 1327.
https://doi.org/10.3390/cancers14051327
|
[33]
|
Zhang, F., Ferrero, M., Dong, N., et al. (2021) Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Cancers, 13, Article 2514.
https://doi.org/10.3390/cancers13112514
|
[34]
|
Verschueren, M.V., van der Welle, C.M.C., Tonn, M., et al. (2021) The Association between Gut Microbiome Affecting Concomitant Medication and the Effectiveness of Immunotherapy in Patients with Stage IV NSCLC. Scientific Reports, 11, Article No. 23331. https://doi.org/10.1038/s41598-021-02598-0
|
[35]
|
Zhang, C., Wang, J., Sun, Z., et al. (2021) Commensal Microbi-ota Contributes to Predicting the Response to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients. Cancer Science, 112, 3005-3017.
https://doi.org/10.1111/cas.14979
|
[36]
|
Song, P., Yang, D., Wang, H., et al. (2020) Relationship between Intestinal Flora Structure and Metabolite Analysis and Immunotherapy Efficacy in Chinese NSCLC Patients. Thoracic Cancer, 11, 1621-1632.
https://doi.org/10.1111/1759-7714.13442
|
[37]
|
Boesch, M., Baty, F., Albrich, W.C., et al. (2021) Local Tumor Mi-crobial Signatures and Response to Checkpoint Blockade in Non-Small Cell Lung Cancer. Oncoimmunology, 10, Article 1988403.
https://doi.org/10.1080/2162402X.2021.1988403
|
[38]
|
Heshiki, Y., Vazquez-Uribe, R., Li, J., et al. (2020) Pre-dictable Modulation of Cancer Treatment Outcomes by the Gut Microbiota. Microbiome, 8, Article No. 28. https://doi.org/10.1186/s40168-020-00811-2
|
[39]
|
Botticelli, A., Vernocchi, P., Marini, F., et al. (2020) Gut Metab-olomics Profiling of Non-Small Cell Lung Cancer (NSCLC) Patients under Immunotherapy Treatment. Journal of Translational Medicine, 18, Article No. 49.
https://doi.org/10.1186/s12967-020-02231-0
|
[40]
|
Liu, T., Xiong, Q., Li, L.L. And Hu, Y. (2019) Intestinal Micro-biota Predicts Lung Cancer Patients at Risk of Immune-Related Diarrhea. Immunotherapy, 11, 385-396. https://doi.org/10.2217/imt-2018-0144
|
[41]
|
Chau, J., Yadav, M., Liu, B., et al. (2021) Prospective Correlation be-tween the Patient Microbiome with Response to and Development of Immune-Mediated Adverse Effects to Immuno-therapy in Lung Cancer. BMC Cancer, 21, Article No. 808. https://doi.org/10.1186/s12885-021-08530-z
|
[42]
|
Yang, J.J., Yu, D.X. and Shu, X.O. (2020) Association of Dietary Fiber and Yogurt Consumption with Lung Cancer Risk: A Pooled Analysis. JAMA Oncology, 6, 788-789. https://doi.org/10.1001/jamaoncol.2020.0270
|
[43]
|
Tomita, Y., Ikeda, T., Sakata, S., et al. (2020) Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer. Cancer Immunology Research, 8, 1236-1242. https://doi.org/10.1158/2326-6066.CIR-20-0051
|
[44]
|
Messaoudene, M., Pidgeon, R., Richard, C., et al. (2022) A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Micro-biota. Cancer Discovery, 12, 1070-1087.
https://doi.org/10.1158/2159-8290.CD-21-0808
|
[45]
|
Lee, S.H., Cho, S.Y., Yoon, Y., et al. (2021) Bifidobacterium bifidum Strains Synergize with Immune Checkpoint Inhibitors to Reduce Tumour Burden in Mice. Nature Microbiology, 6, 277-288.
https://doi.org/10.1038/s41564-020-00831-6
|
[46]
|
Huang, J.M., Liu, D., Wang, Y.W., et al. (2022) Ginseng Poly-saccharides Alter the Gut Microbiota and Kynurenine/Tryptophan Ratio, Potentiating the Antitumour Effect of Antipro-grammed Cell Death 1/Programmed Cell Death Ligand 1 (Anti-PD-1/PD-L1) Immunotherapy. Gut, 71, 734-745. https://doi.org/10.1136/gutjnl-2020-321031
|
[47]
|
Routy, B., Le Chatelier, E., Derosa, L., et al. (2018) Gut Micro-biome Influences Efficacy of PD-1-Based Immunotherapy against Epithelial Tumors. Science, 359, 91-97.
|
[48]
|
Tanoue, T., Morita, S., Plichta, D.R., et al. (2019) A Defined Commensal Consortium Elicits CD8 T Cells and Anti-Cancer Im-munity. Nature, 565, 600-605. https://doi.org/10.1038/s41586-019-0878-z
|